The money is coming from the state’s stem cell agency, which has already spent $2 billion on stem cell research in the last decade. The agency is now on its last $900 million and pushing hard to translate stem cells into therapies and cures. It is expected to run out of money for new awards in 2020.
Earlier this week, a key panel of the agency’s governing board approved the $105 million surge, a decision that is certain to be ratified by the full board at a meeting Dec. 17 in Los Angeles. The action will initiate a 2016 competition for the cash, which is likely to draw national interest, although the money can be spent only within the state.
The largest component of the $105 million is $75 million for a program that the agency has dubbed the “Accelerating Therapies through Public-Private Partnership” or ATP3. The award would be one of the largest ever made by the agency, which is formally known as the California Institute for Regenerative Medicine (CIRM).
Also approved was a $15 million round for an "accelerating center" and another $15 million round for a "translating center." All of the awards are scheduled to be made by late 2016.
Under the ATP3 public-private round, the recipient would be required to match the $75 million from California taxpayers. The program would bundle together for continued CIRM funding the most promising current CIRM projects. Those projects -- a “portfolio of ‘high risk’ but high reward projects” -- would be selected by the recipient for development for commercialization, the agency said in a memo.
CIRM’s plan for the project said,
“The aggregation of a basket of otherwise unpartnered CIRM projects offers the successful applicant ‘multiple shots on goal.’ This increases the probability of successfully developing and commercializing a stem cell treatment and makes significant industry investment in stem cell technology more attractive.”
CIRM’s presentation said the awardee must have a “top-tier” track record and “could be an established company, a spin-off or a new company with a team formed by Pharma, biotechnology or by an investor.”
The other CIRM award rounds that are up for ratification later this month aim also at bringing stem cell therapies into widespread use.
The $15 million accelerating center round, which is open to non-California-based organizations, would fund the following activities:
- “Regulatory management services (including IND preparation and submission)
- “Clinical trial planning and management, including site selection, contracting, and clinical site management (e.g., patient recruitment and operational and logistical support)
- “ Data management, biostatical and analytical services
- “Provision of services to (CIRM’s) Alpha Clinics Network, CIRM-funded investigators and sponsors with translational and clinical stage projects, and clinical sites seeking to join the Alpha Clinics Network”
- “Project planning in coordination with CIRM and the Accelerating Center.
- “Project management for pre-clinical IND-enabling development programs, including pivotal pharmacology and toxicology studies.
- “Process development and product manufacturing activities suitable for production of cell products under good manufacturing practices (GMP).
- “Assembly and authorship of documents to support IND submissions and FDA interactions.
- “Development and execution of a business plan to sustain operations beyond CIRM funding.”